Imaging Prostate Cancer (Pca) Phenotype and Evolution
Abstract
The goal of the project is to investigate the potential of inhibiting iron metabolism to inhibit prostate cancer growth. Specifically, we will study Deferiprone, an iron chelator, and focus on its effect on aconitase in prostate tumors. It has been shown that changes in citrate metabolism at the level of mitochondrial aconitase, is an early change in carcinogenesis in the prostate. This change in metabolism is detectable by magnetic resonance. The project includes both in vitro and in vivo studies to determine its potential utility for clinical translation. Our findings to date include 1) showing that Deferiprone inhibits tumor growth in 2 prostate cell lines, 2) demonstrated an effect on metabolism in perfused cells (one cell line), and 3) confirmed changes in metabolism by measuring changes in oxygen consumption rate. After 24 hours of incubation, deferiprone treated TRAMP C2 cells also showed lower oxygen consumption rates (OCR) and down regulation of mitochondrial aconitase expression, leading to lower enzyme activity as detected in both TRAMP C2 and Myc-Cap cell lines. The effects on both metabolism and proliferation are encouraging and we hope in Year 2 to begin in vivo studies and complete in vitro studies
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA612861
Entities
People
- Jason A Koutcher
Organizations
- Memorial Sloan Kettering Cancer Center